6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
May 1 23:19
6-K: Us Fda Accepts for Priority Review Gsk's Application for an Expanded Indication of Jemperli Plus Chemotherapy to Include All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer
Apr 24 18:48
6-K: Transaction Notification
Apr 19 22:59
6-K: Transaction Notification
Apr 17 22:54
6-K: New Long-Term Data Show Shingrix Continues to Provide High Protection Against Shingles in Adults Aged 50 and over for More Than a Decade
Apr 17 18:14
6-K: Gsk Today Announced Positive Results from the Pivotal Eagle-1 Phase Iii Trial for Gepotidacin
Apr 17 18:09
6-K: The Following Amendments Have Been Made in Accordance with the “director/Pdmr Shareholdings” Announcement Issued by Rns No 6709k
Apr 16 21:55
6-K: GSK's 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA
Apr 16 18:24
GSK PLC | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Apr 15 23:29
GSK PLC | 6-K/A: Report of foreign private issuer [Rules 13a-16 and 15d-16] (Amendment)
Apr 4 19:50
GSK PLC | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Apr 3 01:20
GSK PLC | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Mar 26 19:49
GSK PLC | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Mar 25 21:43
GSK PLC | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Mar 23 00:52
GSK PLC | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Mar 23 00:22
GSK PLC | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Mar 18 21:59
GSK PLC | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Mar 14 01:19
GSK PLC | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Mar 9 01:50
GSK PLC | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Mar 7 19:14
GSK PLC | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Mar 7 00:13
No Data
No Data